- Home
- PMEC vs RNXT Comparison
PMEC vs RNXT Comparison
Compare PMEC & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- RNXT
- Stock Information
- Founded
- PMEC 1984
- RNXT 2012
- Country
- PMEC Singapore
- RNXT United States
- Employees
- PMEC N/A
- RNXT N/A
- Industry
- PMEC
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- RNXT Health Care
- Exchange
- PMEC Nasdaq
- RNXT Nasdaq
- Market Cap
- PMEC 38.4M
- RNXT 35.2M
- IPO Year
- PMEC 2023
- RNXT 2021
- Fundamental
- Price
- PMEC $1.03
- RNXT $0.76
- Analyst Decision
- PMEC
- RNXT Strong Buy
- Analyst Count
- PMEC 0
- RNXT 2
- Target Price
- PMEC N/A
- RNXT $7.50
- AVG Volume (30 Days)
- PMEC 228.9K
- RNXT 388.0K
- Earning Date
- PMEC 01-01-0001
- RNXT 11-13-2025
- Dividend Yield
- PMEC N/A
- RNXT N/A
- EPS Growth
- PMEC N/A
- RNXT N/A
- EPS
- PMEC N/A
- RNXT N/A
- Revenue
- PMEC $74,349,000.00
- RNXT $928,000.00
- Revenue This Year
- PMEC N/A
- RNXT $2,895.35
- Revenue Next Year
- PMEC N/A
- RNXT $313.04
- P/E Ratio
- PMEC N/A
- RNXT N/A
- Revenue Growth
- PMEC 2.52
- RNXT N/A
- 52 Week Low
- PMEC $0.54
- RNXT $0.70
- 52 Week High
- PMEC $2.44
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- PMEC 31.45
- RNXT 34.41
- Support Level
- PMEC $0.81
- RNXT $0.73
- Resistance Level
- PMEC $1.37
- RNXT $0.87
- Average True Range (ATR)
- PMEC 0.17
- RNXT 0.08
- MACD
- PMEC -0.03
- RNXT -0.03
- Stochastic Oscillator
- PMEC 17.13
- RNXT 12.93
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.